{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-018800","form_type":"8-K","ticker":"ACAD","cik":"0001070494","company_name":"ACADIA PHARMACEUTICALS INC","filed_at":"2023-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:37.856536+00:00","generated_at":"2026-06-15T12:05:23.261732+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Acadia Q1 net loss narrows to $43M; DAYBUE approved and launched for Rett syndrome","bullets":["NUPLAZID net sales $118.5M, up 3% YoY; demand grew ~2%.","Net loss $43.0M ($0.27/share) vs $113.1M ($0.70/share) in Q1 2022.","DAYBUE (trofinetide) FDA-approved March 10; launched April 17 for Rett syndrome.","Phase 3 pimavanserin trial for negative schizophrenia symptoms nearing enrollment; results expected early 2024.","2023 guidance reaffirmed: NUPLAZID sales $520-$550M, R&D $235-$255M, SG&A $360-$380M."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-018800","json":"https://secwatch.observer/filing/0000950170-23-018800.json","markdown":"https://secwatch.observer/filing/0000950170-23-018800.md","text":"https://secwatch.observer/filing/0000950170-23-018800.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1070494/000095017023018800/0000950170-23-018800-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1070494/000095017023018800/acad-20230508.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T12:05:23.261732+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b5cb80729df1ee4e439673626f85cdf2cc403acb","claim":"ACADIA PHARMACEUTICALS INC reported three months ended March 31, 2023 results: revenue $118.5 million, net income $43.0 million, or $0.27 per common share, EPS $0.27 per common share. Guidance reaffirmed.","evidence_excerpt":"language. --- EX-99 (EX-99.1) --- EX-99 Exhibit 99.1 Acadia Pharmaceuticals Reports First Quarter 2023 Financial Results and Operating Overview - 1Q23 NUPLAZID ® net sales of $118.5 million - Announced the U.S. FDA Approval of DAYBUETM (trofinetide) for the Treatment of Rett Syndrome in Adult and Pediatric Patients Two Years of Age and Older on March 10, 2023 -","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1070494/000095017023018800/0000950170-23-018800-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three months ended March 31, 2023"},{"label":"Revenue","value":"$118.5 million"},{"label":"Net income","value":"$43.0 million, or $0.27 per common share"},{"label":"EPS","value":"$0.27 per common share"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}